Compare CQP & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CQP | BIIB |
|---|---|---|
| Founded | 2003 | 1978 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.2B | 24.2B |
| IPO Year | 2007 | 1991 |
| Metric | CQP | BIIB |
|---|---|---|
| Price | $55.99 | $177.88 |
| Analyst Decision | Strong Sell | Buy |
| Analyst Count | 6 | 24 |
| Target Price | $53.33 | ★ $181.77 |
| AVG Volume (30 Days) | 78.3K | ★ 1.6M |
| Earning Date | 02-19-2026 | 02-06-2026 |
| Dividend Yield | ★ 5.89% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 3.84 | ★ 10.97 |
| Revenue | ★ $10,308,000,000.00 | $10,065,900,000.00 |
| Revenue This Year | $25.52 | $3.61 |
| Revenue Next Year | $4.57 | N/A |
| P/E Ratio | ★ $14.68 | $16.39 |
| Revenue Growth | ★ 15.43 | 4.77 |
| 52 Week Low | $49.53 | $110.04 |
| 52 Week High | $68.42 | $190.20 |
| Indicator | CQP | BIIB |
|---|---|---|
| Relative Strength Index (RSI) | 57.91 | 55.34 |
| Support Level | $55.70 | $170.85 |
| Resistance Level | $58.00 | $176.14 |
| Average True Range (ATR) | 1.27 | 5.21 |
| MACD | 0.06 | 0.42 |
| Stochastic Oscillator | 66.00 | 69.19 |
Cheniere Energy Partners is a liquified natural gas producer operating one facility in Sabine Pass, Louisiana. It generates most of its revenue through long-term contracts with customers on a fixed- and variable-fee payout structure. It also generates revenue by selling uncontracted LNG to customers on a short or one-time basis. The profit generated through those activities is split with parent and operator Cheniere Energy.
Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).